The information in this section is intended for physicians and healthcare professionals only.

Click here for references

ELESTAT® ophthalmic solution is convenient to use. The recommended dosage is 1 drop in each eye twice a day. Please keep in mind that treatment should be continued throughout the period of exposure (until pollen season is over or until exposure to the offending allergen ends), even when symptoms are not present.





©2006 Inspire Pharmaceuticals, Inc., Durham, NC 27703 ® Marks owned by Allergan, Inc. Inspire and the Inspire logo are registered trademarks of Inspire Pharmaceuticals, Inc. ELESTAT® is licensed from Boehringer Ingelheim Pty. Ltd., Ingelheim, Germany.


ELESTAT® ophthalmic solution is indicated for the prevention of ocular itching associated with allergic conjunctivitis.

Important Safety Information:
ELESTAT® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to epinastine or to any of the other ingredients.

Patients should be advised not to wear a contact lens if their eye is red. ELESTAT® ophthalmic solution should not be used to treat contact lens related irritation. The preservative in ELESTAT®, benzalkonium chloride, may be absorbed by soft contact lenses.Contact lenses should be removed prior to instillation of ELESTAT® ophthalmic solution and may be reinserted after 10 minutes following its administration.

The most frequently reported ocular adverse events occuring in approximately 1% to 10% of patients were burning sensation in the eye, folliculosis, hyperemia, and pruritus. The most frequently reported nonocular adverse events were infection (cold symptoms and upper respiratory infections), seen in approximately 10% of patients, and headache, rhinitis, sinusitis, increased cough, and pharyngitis seen in approximately 1% to 3% of patients. Some of these events were similar to the underlying disease being studied.

Please see prescribing information for ELESTAT®.